Question explored with the scientific record
Conversation so far
- 1 What does long term pregabalin use do to you?
- 2 What withdrawal symptoms and timeline are reported after stopping?
Answered on this page ↓
What withdrawal symptoms and timeline are reported after stopping?
The short version: withdrawal from pregabalin is real, predictable, and poorly quantified in the evidence you have in front of you.
The evidence here was not designed to study withdrawal. It studies pregabalin as a treatment for other drug dependencies, which tells you the drug acts on the same brain systems that produce withdrawal [1, 2]. One review uses pregabalin to treat alcohol and benzodiazepine dependence [1]. Another uses it to improve sleep during benzodiazepine withdrawal [2]. That is indirect evidence: if a drug treats withdrawal from another substance, it is almost certainly capable of producing its own withdrawal syndrome when stopped.
What the evidence does show is that pregabalin changes brain chemistry in ways that make dependence likely. The drug is a calcium channel modulator that suppresses nerve firing [3, 7]. After weeks or months of use, the brain adapts. When the drug is removed, the suppressed systems rebound. That rebound is withdrawal. The symptom cluster is well documented outside this retrieval: anxiety, insomnia, agitation, sweating, nausea, and in severe cases confusion or seizures. The timeline typically starts within 12 to 24 hours of the last dose, peaks in the first week, and resolves over two to four weeks, though some patients report lingering symptoms for months.
The evidence here does not give you a single number for how many patients experience withdrawal or how severe it is. That is a gap. The manufacturer-funded trials report dizziness and somnolence as common side effects during treatment [11], but they do not report what happens when the drug is stopped. The most informative study design, a prospective cohort that follows patients through discontinuation and measures withdrawal systematically, was not run or was not published.
My call: pregabalin withdrawal is a real and predictable consequence of long-term use, with a symptom cluster that emerges within a day and typically resolves over weeks, but the evidence here does not quantify the risk or severity. Confidence: moderate, because the mechanism is well understood and the indirect evidence is consistent, but the direct evidence is missing.
Sources examined 12
-
Pregabalin in the Treatment of Alcohol and Benzodiazepines Dependence
This review evaluates the efficacy and safety of pregabalin in treating alcohol and benzodiazepine dependence, highlighting its potential as a novel therapeutic option despite the limitations of the studies reviewed.
DOI: 10.1111/j.1755-5949.2009.00120.x -
PW01-241 - The Effect Of Pregabalin On Subjective Sleep Problems During Withdrawal From Long-Term Benzodiazepine Use
This study evaluates whether pregabalin used during tapering aids subjective sleep quality in adults withdrawing from long-term benzodiazepine use, reporting substantial MOS-Sleep improvements and correlations with anxiety and illness severity in a 12-week observational analysis.
DOI: 10.1016/s0924-9338(10)71648-5 -
Fibromyalgia syndrome: epidemiology, diagnosis and treatment
Fibromyalgia syndrome is a common chronic pain disorder with evolving diagnostic criteria and multimodal management integrating drugs like pregabalin and duloxetine with exercise, CBT, and education.
DOI: 10.5114/reum.2022.123671 -
A Case Report on Pregabalin-Induced Eosinophilia
This case report describes a 77-year-old diabetic patient who developed eosinophilia likely induced by pregabalin, which resolved after discontinuation of the drug.
DOI: 10.4140/TCP.n.2018.317 -
Patient with insidious hypoactive delirium associated with pregabalin
This case report describes a 68-year-old patient who developed insidious hypoactive delirium associated with pregabalin therapy for postherpetic neuralgia, which improved after discontinuation of the medication.
DOI: 10.1111/ncn3.48 -
A Case of Drug-Induced Pancytopenia due to Tamoxifen
This case report describes a 46-year-old woman with breast cancer who developed severe pancytopenia temporally associated with tamoxifen therapy (with possible contribution from pregabalin), followed by spontaneous recovery after drug discontinuation, highlighting tamoxifen as a…
DOI: 10.70352/scrj.cr.25-0227 -
Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report
This case report describes a 28-year-old female patient who developed neuropsychiatric symptoms and thrombocytopenia following pregabalin treatment for neuralgia, highlighting the need for careful monitoring of patients on this medication.
DOI: 10.1007/s11096-014-0026-7 -
Pregabalin relieves symptoms of painful diabetic neuropathy
A multicenter, randomized, double-blind, placebo-controlled trial demonstrating that pregabalin at 300 and 600 mg/day provides early and sustained relief of pain and sleep interference in diabetic peripheral neuropathy, with the 75 mg/day dose being ineffective and pregabalin ge…
DOI: 10.1212/01.wnl.0000145767.36287.a1 -
A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
This randomized, double-blind, multicenter phase III trial in Japan shows that pregabalin up to 450 mg/day significantly reduces pain and improves sleep and functioning in Japanese patients with fibromyalgia, with a manageable safety profile.
DOI: 10.1186/ar4056 -
Hypomanic Episode Upon Venlafaxine Discontinuation
This case report documents a hypomanic switch occurring during slow discontinuation of venlafaxine in a 48-year-old woman with a history of recurrent depression, highlighting a potential antidepressant-discontinuation–associated mood change and the need for further study.
DOI: 10.1016/s0924-9338(15)30913-5 -
A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain
This Pfizer-sponsored analysis pooled patient-level data from 31 randomized trials of pregabalin in peripheral neuropathic pain to characterize the incidence and timing of adverse events, compare across doses and disease conditions, and advocate careful dose titration to maximiz…
DOI: 10.1111/papr.12146 -
Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia
A pooled analysis of pregabalin trials in fibromyalgia shows meaningful improvements in fatigue, function, and self-reported presenteeism at 450 mg/day, with supportive long-term safety data from open-label extensions, and supplementary analyses on milnacipran's PGIC relationshi…
DOI: 10.1016/j.jpain.2009.01.303